Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Alexion

Soliris product sales up 20% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion

3Q Revenues: $666.6 million (+20%)

3Q Loss: $183.8 million (earnings were $177 million 3Q14)

YTD Revenues: $1.9 billion (+16%)

YTD Earnings: $77.8 billion (earnings were $503.6 million YTD14)

Comments: Soliris product sales were $665.4 million in the quarter, up 20%. Results reflect Synageva’s operations for the first full quarter following the close of the acquisition in June. Strensiq was approved by the FDA under Breakthrough Therapy Designation and Priority Review for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP). Strensiq was also approved in the EU, Japan and Canada. Restructuring expenses were $7.5 million in the quarter and includes $3.2 million resulting from the Synageva acquisition and $4.3 million related to the European headquarters relocation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters